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ABSTRACT
Objectives  To explore the relationship of serious infection 
risk with current and prior oral glucocorticoid (GC) therapy 
in elderly patients with rheumatoid arthritis (RA). 
Methods  A case-control analysis matched 1947 serious 
infection cases to ﬁ  ve controls, selected from 16207 
RA patients aged ≥65 between 1985–2003 in Quebec, 
Canada. Adjusted odds ratios for infection associated 
with different GC patterns were estimated using 
conventional models and a weighted cumulative dose 
(WCD) model.
Results  The WCD model predicted risks better than 
conventional models. Current and recent GC doses 
had highest impact on current risk. Doses taken up 
to 2.5 years ago were also associated with increased 
risk, albeit to a lesser extent. A current user of 5mg 
prednisolone had a 30%, 46% or 100% increased 
risk of serious infection when used continuously for 
the last 3 months, 6 months or 3 years, respectively, 
compared to a non-user. The risk associated with 
5mg prednisolone taken for the last 3 years was 
similar to that associated with 30mg taken for the 
last month. Discontinuing a two-year course of 10mg 
prednisolone six months ago halved the risk compared 
to ongoing use.
Conclusions  GC therapy is associated with infection 
risk in older patients with RA. The WCD model provided 
more accurate risk estimates than conventional models. 
Current and recent doses have greatest impact on 
infection risk, but the cumulative impact of doses taken 
in the last 2–3 years still affects risk. Knowing how 
risk depends on pattern of GC use will contribute to an 
improved beneﬁ  t/harm assessment.
Glucocorticoid therapy continues to be widely used 
as a treatment for patients with rheumatoid arthri-
tis (RA).1 2 Although effective,3 4 there are concerns 
about infection and other safety outcomes includ-
ing cardiovascular disease, diabetes, weight gain, 
cataracts and osteoporosis.5 Surprisingly, after over 
60 years of experience, it is not clear how the risk 
of these outcomes depends on treatment regimes, 
what degree of risk is conferred, or what happens 
to risk on stopping therapy. We cannot accurately 
inform patients of the potential harms (as suggested 
in recent guidelines)6 if the risks are not accurately 
quantiﬁ  ed.
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Serious infection is one of the major causes 
of increased mortality in patients with RA.7 
Glucocorticoid therapy is a likely mediator as it 
impairs phagocyte function and suppresses cell-
mediated immunity.8 High-dose glucocorticoid 
therapy is associated with an increased risk of 
infection in other diseases,9 but the relationship 
with lower doses used in RA is less clear.10
Existing methods to quantify infection risk with 
glucocorticoid therapy have notable limitations. 
Randomised controlled trials in RA have small 
numbers of patients (only one >250 patients),11 
short follow-up, and variable reporting of safety 
outcomes.10 Observational studies typically over-
come all three limitations. Their ‘real-life’ setting, 
however, introduces analytical challenges. In 
addition to confounding, the lack of a prespeciﬁ  ed 
treatment protocol means, particularly for gluco-
corticoid therapy, that treatment regimens vary 
between patients and change with time. Previous 
observational studies reporting glucocorticoid-as-
sociated infection risk have used exposure mod-
els such as ‘current use’, ‘recent use’, ‘ever use’ 
or ‘total past dose’.12–17 These models ignore pat-
terns of drug use with time; an important factor 
for glucocorticoid therapy in RA in which doses 
are continually increased, reduced or stopped. 
Furthermore, most studies select a priori one or, 
at most, few models for glucocorticoid exposure 
representation, and do not attempt to investi-
gate if alternative models may ﬁ  t their data bet-
ter. Novel analytical methods exist to model a 
past history of drug use ﬂ  exibly up to the time 
point when risk is being assessed.18 These meth-
ods represent exposure history by the weighted 
cumulative dose (WCD) of the drug of interest, 
with previous doses weighted according to their 
recency.19
The aim of this study was therefore to examine 
the association between the risk of serious infec-
tion and real-life patterns of glucocorticoid therapy 
in patients with RA. To this end, we performed 
a nested case–control analysis using data from a 
Canadian administrative database. To account for 
variation in the dosage, duration and timing of glu-
cocorticoid therapy, and to explore how the risk 
depends on the treatment regimen, we employed 
the WCD model and compared the results with tra-
ditional approaches.
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on the same date following an RA code and DMARD use, 
had the same sex and similar age, had not developed a seri-
ous infection by the corresponding index date, but who were 
still under follow-up. For each case, from the respective risk 
set we randomly selected ﬁ  ve controls. Controls could later be 
included as cases, and the same patient could be selected as a 
control for different cases.
Exposure
All drugs dispensed before the index date were identiﬁ  ed from 
the prescription database. Systemic glucocorticoid therapy (oral, 
intravenous or intramuscular injection) was identiﬁ  ed using the 
drug product database of Health Canada.20 Oral glucocorticoid 
dosage was averaged across each prescription period (derived 
directly from the prescription database) and converted to daily 
prednisolone equivalent dosage (PEQ). Injectable (intramuscular 
or intravenous) glucocorticoid therapy was adjusted for in the 
analysis using the number of prescriptions of injectable gluco-
corticoids in each of the three time periods: 0–6 months; 7–12 
months and 1–5 years.
Confounders
Disease severity, other immunosuppressants and co-morbidity 
were potential confounders. In the absence of direct measures of 
disease severity, surrogate markers were used (number of rheu-
matologist visits in the preceding year, current non-steroidal anti-
inﬂ  ammatory drug (NSAID) use).21 All analyses were adjusted 
for concomitant DMARD exposure, deﬁ  ned as a DMARD pre-
scription in the 45 days before the index date. Comorbidity was 
identiﬁ  ed from diagnoses before the index date (chronic respira-
tory conditions, osteoporosis, cancer, diabetes and chronic renal 
PATIENTS AND METHODS
Study base
Patients with RA were identiﬁ  ed from the administrative data-
bases of the Régie de l’assurance maladie du Québec and the 
Maintenance et Exploitation des Données pour l’Étude de la 
Clientèle Hospitalière, in Quebec, Canada.16 Brieﬂ  y, linked data 
are available on demographics, medical services including diag-
nostic codes for billed services and hospital admission data. For 
patients aged 65 years and older, data were available on date, 
duration and dose of each prescription dispensed.
Study population
The sampling frame consisted of all patients with RA aged 65 
years and older who, between 1 January 1985 and 31 December 
2003, were dispensed at least one traditional or biological disease-
modifying antirheumatic drug (DMARD). RA was identiﬁ  ed on 
the basis of at least one physician billing code (International 
Classiﬁ  cation of Disease, version 9 (ICD-9) code 714). Cohort 
entry was deﬁ  ned as the date of ﬁ  rst DMARD prescription fol-
lowing an RA diagnosis. All subjects were followed from cohort 
entry date to the earliest of serious infection, death or the end 
of the study period (31 March 2004). Subjects were required to 
have more than 3 months of eligibility in the health insurance 
plan before cohort entry.
Deﬁ  nition of cases and controls
Serious infection cases were identiﬁ  ed as the ﬁ  rst occurrence 
of a primary hospital discharge diagnosis of infection (see sup-
plementary ﬁ  le for ICD codes, available online only), which 
deﬁ  ned the index date. For each case of serious infection, we 
identiﬁ  ed a risk set of patients with RA who joined the cohort 
Table 1  Baseline characteristics of cases and controls
  Cases Controls
Number 1947 9735
Age in years, median (IQR)* 74 (70–79) 74 (70–79)
Sex (% women)* 66.1 66.1
Follow-up in years, median (IQR)* 3.0 (1.2–5.8) 3.0 (1.2–5.8)
No of rheumatologist visits in the 6 months before index date, median (IQR) 0 (0–2) 0 (0–1)
NSAID prescription within past 45 days (%) 52.5 46.7
DMARD prescription within past 45 days (%)†
Methotrexate 30.1 27.5
Sulfasalazine 1.8 2.1
Leﬂ  unomide 0.6 0.3
Chloroquine/hydroxychloroquine 20.9 21.6
Azathioprine 2.8 1.5
Cyclophosphamide 2.3 0.5
Anti-TNF therapy 0.3 0.1
Gold 4.8 5.5
Others (ciclosporin, mycophenolate mofetil, D-penicillamine) 1.1 1.0
No of hospital admissions in year preceding index date, median (IQR) 0 (0–1) 0 (0–1)
No of GP visits in year preceding index date, median (IQR) 7 (3–14) 5 (1–9)
No of hospital specialist visits (excluding rheumatologist) in year preceding 
index date, median (IQR)
8 (3–16) 5 (2–10)
Co-morbidity (from ICD-9 or drug codes) (%)
Chronic respiratory disease (COPD/asthma/ILD) 26.5 15.7
Osteoporosis 24.8 17.5
Chronic renal disease 0.4 0.1
Cancer 4.3 1.7
Diabetes 8.4 6.0
PPI/H2 blocker prescription within past 45 days (%) 36.6 24.1
*Variables used for matching.
†Patients could be on more than one DMARD and contribute to more than one category.
COPD, chronic obstructive pulmonary disease; DMARD, disease-modifying antirheumatic drug; GP, general practitioner; ILD, 
interstitial lung disease; NSAID, non-steroidal  
anti-inﬂ  ammatory drug; PPI, proton-pump inhibitor; TNF, tumour necrosis factor.
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Flexible weighted cumulative dose model
Finally, in the WCD model,19 glucocorticoid exposure was 
represented as the weighted sum of past oral doses, with 
weights estimated so as to reﬂ  ect the relative importance of 
disease). These comorbidities were also identiﬁ  ed from medi-
cation typically associated with their treatment. Diabetes was 
included as a confounder only if the onset of diabetes preceded 
the ﬁ  rst glucocorticoid prescription, thereby avoiding diabetes 
being on a causal pathway from glucocorticoid use to infection. 
All models also adjusted for age, number of hospital admissions, 
number of general practitioner (GP) and hospital specialist visits 
in the preceding year and concomitant use of gastric acid-sup-
pressive drugs.22
Statistical analyses
Primary analyses assessed the impact of glucocorticoid exposure 
on serious infection risk. We employed multivariable conditional 
logistic regression to contrast the exposure patterns between 
cases and their matched controls. Because of the uncertainty 
about the mechanisms linking glucocorticoid exposure and the 
risk of serious infection, we estimated several multivariable 
models, each representing glucocorticoid exposure differently. 
All available cases were included rather than performing a for-
mal sample size calculation to determine study size.
Conventional models
The ﬁ  rst 10 models used conventional exposure metrics often 
employed in pharmacoepidemiology. Models 1–4 disregarded 
information on glucocorticoid dose and represented exposure by 
binary indicator variables of: (1) current use on the index date; or 
any use in: (2) the previous 30 days; (3) 90 days; (4) or any time 
in the past (indicator of ever exposed). Model 5 used a quantita-
tive measure of current daily oral dose at the index date. Models 
6–8 deﬁ  ned the exposure metric as average past oral dose taken 
over a relevant time window, corresponding to previous (6) 30 
days or (7) 90 days, or (8) the entire time since the subject’s entry 
into the cohort. Models 9–10 used the peak oral dose over (9) 
the previous 30 days or (10) 90 days.
Figure 1  Estimated weight function (solid curve) and pointwise 95% 
bootstrap CI (dotted curves) for the ﬁ  nal weighted cumulative dose 
model of the association between previous oral glucocorticoid exposure 
and serious infection. The ﬁ  nal WCD model used 3 degrees of freedom 
to model the weight function (see Supplementary Online Materials). 
Relative risks associated with speciﬁ  c exposure patterns are derived 
from the weighted sum of past doses, with weights shown on the 
y-axis. Accordingly, the total impact of continuing exposure (in terms 
of log OR) during a given time period corresponds to the area under the 
weight curve (over the corresponding time interval).
Table 2  Relationship between serious infection risk and oral glucocorticoid exposure for the 10 conventional models and the best ﬁ  tting cumulative 
weighted dose model
Model
Among cases 
(% or mean)*
Among controls 
(% or mean)* OR (95% CI)†
OR for 5 mg increase 
(95% CI) AIC‡
AIC–AIC of the WCD 
model
Binary conventional models
(1) Current use 42.1% 24.7% 1.84 (1.64 to 2.06) - 6175.0 115.2
(2) Any use past 30 days 52.9% 31.1% 2.08 (1.86 to 2.33) - 6122.1 62.3
(3) Any use past 90 days 58.6% 34.7% 2.26 (2.02 to 2.54) - 6083.6 23.8
(4) Ever use 74.4% 58.5% 1.72 (1.53 to 1.94) - 6201.5 141.7
Dose-speciﬁ  c conventional models
(5) Current dosea 11.0 mg PEQ 7.8 mg PEQ 1.04 (1.04 to 1.05) 1.24 (1.19 to 1.30) 6171.3 111.4
(6) Average dose in past 30 daysb 8.3 mg PEQ 6.2 mg PEQ 1.07 (1.06 to 1.08) 1.41 (1.33 to 1.49) 6124.0 64.2
(7) Average dose in past 90 daysb 7.1 mg PEQ 5.4 mg PEQ 1.09 (1.08 to 1.11) 1.56 (1.46 to 1.67) 6094.8 34.9
(8) Average dose since study entryb 5.4 mg PEQ 3.7 mg PEQ 1.08 (1.06 to 1.09) 1.45 (1.35 to 1.56) 6166.6 106.8
(9) Peak dose in past 30 daysc 13.6 mg PEQ 9.3 mg PEQ 1.03 (1.02 to 1.03) 1.14 (1.10 to 1.17) 6187.3 127.5
(10) Peak dose in past 90 daysc 15.2 mg PEQ 10.9 mg PEQ 1.02 (1.01 to 1.02) 1.10 (1.07 to 1.12) 6200.3 140.5
Flexible model incorporating weighting by recency of treatment
(11) Final WCD (3-year with 3 degrees 
of freedom)
§ § § § 6059.8 0 (minimum AIC)
OR, adjusted for all a priori confounders.
*For models representing exposure by binary indicator variables (1–4), the value provided is the proportion of cases/controls with the deﬁ  ned glucocorticoid exposure. For models with 
continuous exposure (5–10), the mean value of the exposure variable among glucocorticoid therapy users for cases/controls is given (seea–c below).
†For dose-speciﬁ  c models (5–10), OR represents risk per 1 mg PEQ increase.
‡A lower AIC value indicates a better ﬁ  t to data.
§Because the (non-parametric) WCD model estimates exposure effect using ﬂ  exible spline functions, the estimated effect cannot be summarised by a single parameter. See ﬁ  gure 1 for 
the estimated weight function and table 3 for the WCD model estimates of adjusted OR associated with selected exposure patterns.
aMean current dose=mean dose in current users.
bAverage dose in past 30/90 days/since study entry=average dose over the past 30/90 days/since study entry in subjects who used glucocorticoid therapy for at least 1 day in past 
30/90 days since study entry.
cMean peak dose in past 30/90 days=mean peak dose in past 30/90 days in subjects who used glucocorticoid therapy for at least 1 day in past 30/90 days.
AIC, Akaike information criterion; PEQ, prednisolone equivalent; WCD, weighted cumulative dose.
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doses taken at different times. The weights assigned to past 
doses were estimated using a ﬂ  exible cubic spline technique 
that avoided a priori assumptions regarding the shape of the 
weight function.23
Because of the uncertainty regarding the time window over 
which past glucocorticoid exposure may affect the current risk 
of serious infection, six alternative WCD models with exposure 
time windows corresponding to previous 1 or 3 months, or 1, 
2, 3 or 4 years were ﬁ  tted. Procedure and criteria used to select 
the ﬁ  nal WCD model are described in detail in the supplemen-
tary materials, available online only. Models’ goodness of ﬁ  t was 
compared based on the minimum Akaike information criterion 
(AIC).24 For benchmarking, any AIC difference bigger than 10 is 
considered very important.25
RESULTS
Among 16 207 patients with RA aged 65 years or older, 1947 
developed a ﬁ  rst serious infection after an average of 3.8 years 
follow-up. These were matched to 9735 controls, each case 
successfully matched to ﬁ  ve controls. Cases had more severe 
disease as evidenced by a higher number of rheumatolo-
gist and GP visits in the preceding year and more NSAID use 
(table 1). Cases also had higher levels of comorbidity. There 
were no missing data.
The relationships between serious infection and glucocorti-
coid exposure, estimated through the 10 conventional models, 
are described in table 2. All models indicated statistically signiﬁ  -
cant associations between glucocorticoid exposure and serious 
infection (p<0.0001, data not shown). However, the goodness 
of ﬁ  t, quantiﬁ  ed by AIC, of different models varied considerably 
depending on the way glucocorticoid exposure was represented, 
the time window over which it was considered, and whether the 
glucocorticoid doses were taken into account. Among the con-
ventional models, the best ﬁ  t (lowest AIC) was obtained with any 
use in the past 90 days (model 3), followed by average dose in the 
past 90 days (model 7). Average dose, or any use, in the past 30 
days (models 6 and 2) provided the next best ﬁ  t. All other con-
ventional models including current use, ever use and average past 
dose (models 1, 4 and 8) provided a notably worse ﬁ  t (table 2).
Among the alternative WCD models, those estimating 
weighted cumulative exposure over the past 1–4 years ﬁ  tted the 
data much better than those assuming shorter windows of aeti-
ologically relevant exposure (data not shown). The best-ﬁ  tting 
ﬁ  nal WCD model corresponded to the 3-year window model. 
The ﬁ  nal WCD model predicted serious infections much better 
than any of the conventional models, whose AIC were more 
than 20–140 units higher (table 2), recalling that a 10 unit differ-
ence is considered very important.25 As explained in section 3 of 
the supplementary materials (available online only), such differ-
ences may be interpreted as the evidence that the WCD model 
provides statistically very signiﬁ  cant improvements in the pre-
diction of outcomes, compared with all conventional models (all 
p values <0.0001).
The estimated weight function for the ﬁ  nal best-ﬁ  tting ﬂ  exi-
ble WCD model is shown in ﬁ  gure 1. The horizontal axis shows 
time (t) before the index date and the vertical axis shows the 
corresponding estimated weights, reﬂ  ecting the relative strength 
of the impact of glucocorticoid doses taken t months ago on the 
current risk of infection. As expected, the current and very recent 
doses (near t=0) have the highest impact on current risk, and the 
effect of past doses decreases sharply with increasing time since 
exposure. Still, even doses taken approximately half a year ago 
seem to have some impact on the current risks. Interestingly, the 
weight function suggests that, in addition to the effect of gluco-
corticoid exposure in the past 6 months, doses taken up to 2.5 
years ago are also associated with increased current risk. These 
‘remote’ doses have relatively low weights but, if taken for a 
long time, can lead to an important cumulative effect.
In sensitivity analyses, we re-estimated the WCD models for 
two separate subsamples, each of which was restricted to the 
case–control risk sets corresponding to infections that occurred 
before or after 1 January 1996 (565 and 1382 cases, respectively). 
The estimated weight functions obtained for both calendar 
year-stratiﬁ  ed analyses were quite similar to the estimate for the 
entire sample, shown in ﬁ  gure 1 (data not shown). This indi-
cated that our estimates are not materially affected by potential 
changes in glucocorticoid prescribing that may have occurred 
during the study period (1985–2004). Furthermore, to verify the 
Table 3  Adjusted OR (with 95% bootstrap CI) for the association between various clinical patterns of glucocorticoid therapy during the past 3 years 
and risk of current serious infection
Pattern of use Reference Adjusted OR (95% CI)*
Current user, 5 mg, for past 7 days Non-user 1.03 (1.02 to 1.11)
Current user, 5 mg, for past 28 days Non-user 1.11 (1.08 to 1.26)
Current user, 5 mg, for past 3 months Non-user 1.30 (1.21 to 1.45)
Current user, 5 mg, for past 6 months Non-user 1.46 (1.31 to 1.65)
Current user, 5 mg, for past 1 year Non-user 1.55 (1.41 to 1.88)
Current user, 5 mg, for past 3 years Non-user 2.00 (1.69 to 2.26)
Past user, 5 mg, for 6 months, stopped 6 months ago Non-user 1.06 (0.98 to 1.27)
Current user, 5 mg, for past 6 months Past user, 5 mg, for 6 months, stopped 6 months ago 1.38 (1.07 to 1.61)
Current user, 30 mg, for past 7 days Non-user 1.18 (1.13 to 1.86)
Current user, 30 mg, for past 28 days Non-user 1.84 (1.58 to 4.00)
Current user, 30 mg, for past 3 months Non-user 4.82 (3.12 to 9.29)
Current user, 30 mg, for past 6 months Non-user 9.81 (5.13 to 19.92)
Current user, 30 mg, for past 30 days Past user, 30 mg, for 30 days, stopped 14 days ago 1.07 (1.04 to 2.87)
Current user, 30 mg, for past 30 days  Past user, 30 mg, for 30 days, stopped 28 days ago 1.13 (1.07 to 4.30)
Current user, 30 mg, for past 30 days Past user, 30 mg, for 30 days, stopped 3 months ago 1.40 (1.20 to 3.66)
Current user, 30 mg, for past 14 days Past user, 30 mg, for 14 days, stopped 28 days ago 1.06 (1.03 to 2.79)
Current user, 10 mg, for past 2 years Past user, 10 mg, for 2 years, stopped 2 weeks ago 1.10 (1.06 to 1.41)
Current user, 10 mg, for past 2 years Past user, 10 mg, for 2 years, stopped 1 month ago 1.20 (1.12 to 1.61)
Current user, 10 mg, for past 2 years Past user, 10 mg, for 2 years, stopped 3 months ago 1.55 (1.33 to 2.03)
Current user, 10 mg, for past 2 years Past user, 10 mg, for 2 years, stopped 6 months ago 1.87 (1.32 to 2.63)
*Adjusted OR represents the relative risk of infection for the pattern of use in column one compared with the reference pattern of use in column two.
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effect on infection risk. A ‘recent exposure’ model considering 
use in the past 30 days assumes treatment received 29 days ago 
is important but 31 days ago carries no risk. In ‘ever exposed’ 
models, 10 mg PEQ taken several years ago carries the same 
risk as 10 mg taken now. Because previous analyses have tended 
to select only one of these models, clinicians are left uncertain 
about the temporal relationship between glucocorticoid use 
and infection. In contrast, our ﬂ  exible WCD model19 accounts 
directly for the variation in glucocorticoid timing by assigning 
differential weights to doses taken at different time intervals in 
the past.
The WCD model provided a far better ﬁ  t to our data than any 
of the conventional models and, thus, provided strong evidence 
that the risk of infection cumulated over past glucocorticoid 
use but also varied with the dose and recency of treatment. We 
have shown that cumulative effects affect the risk of infection 
even 2–3 years later and accounting for such long-term effects 
improves risk prediction. For example, whereas 5 mg PEQ car-
ries a 11%, 30% or 55% increased risk of infection compared 
with non-users if taken for 1, 3 or 12 months, respectively, the 
same dose taken for 3 years would lead to a 100% risk increase 
(table 3). This additional increase in risk from 55% to 100%, 
when extending continuing glucocorticoid exposure from 1 to 3 
years, results from the cumulative effect of long-term exposure 
over two additional years, even though the weights assigned 
to doses taken 1–3 years ago are signiﬁ  cantly lower than the 
weights assigned to more recent doses (ﬁ  gure 1). This is impor-
tant as many physicians consider 5 mg PEQ a ‘physiological 
dose’ that may not have important harms. We have also been 
able to explore the impact of glucocorticoid discontinuation. For 
example, we have shown that 5 mg PEQ is associated with an 
OR of 1.46 compared with a non-user if used continuously for 
the past 6 months, but that this risk falls to only 1.06 if the same 
exposure occurred between 12 and 6 months ago, ie, was dis-
continued 6 months ago (table 3).
Knowledge of time-varying risk can contribute more fully to 
the beneﬁ  t/harm balance of glucocorticoid use in clinical practice, 
for example before elective procedures. Continuing a 1-month 
course of 30 mg prednisolone up to the date of surgery may 
be associated with up to a 13–40% higher risk than stopping 
1–3 months earlier (table 3). Equally important, a shorter 2-week 
course of 30 mg prednisolone carries little additional risk if taken 
immediately before the date of interest, compared with a course 
of the same duration that is discontinued 1 month earlier.
Having deﬁ  ned the shape of the estimated weight function in 
ﬁ  gure 1, we should consider possible explanations for the pat-
tern of the relationship between infection risk and current and 
past doses, be they causal or otherwise. As expected, current 
and recent glucocorticoid therapy has the strongest association 
with current risk. Glucocorticoids act on both the innate and 
adaptive immune system. Impaired innate immunity would 
be expected to have an immediate impact, but may be pre-
dicted to recover following glucocorticoid discontinuation. Our 
data show that ‘remote’ therapy has a lesser, but still impor-
tant, impact. The effects on adaptive immunity, which include 
T-lymphocyte apoptosis, may be long-standing and include 
failure to generate pathogen-speciﬁ  c adaptive immune respons-
es.28 Furthermore, trophic effects of glucocorticoids on connec-
tive tissue may impair barrier function and result in long-term 
changes in host vulnerability to infection, for example skin 
atrophy. The ﬁ  nding of a non-negligible, statistically signiﬁ  cant 
effect of glucocorticoid use between 1 and 3 years ago on the 
current risk of serious infection may reﬂ  ect an integrated effect 
of multiple glucocorticoid-regulated phenomena, each with a 
shape of the weight function, we estimated models in which 
glucocorticoid exposure was represented by a series of seven 
separate variables, each corresponding to a speciﬁ  c (mutually 
exclusive) time interval (past 3 months, 3–6 months ago, 6–12 
months ago, …, 30–36 months ago). Glucocorticoid exposure 
was modelled for each of these intervals using binary indica-
tors of ‘any use’ (similar to models 2–3 in table 2) or ‘average 
dose’ (similar to models 6–7). Reassuringly, consistent with our 
ﬁ  nal WCD model, the strongest association was found for doses 
taken in the most recent 3 months, a weaker association for 
months 3–6 and 6–12, no association for months 12–18, a return 
of a weak positive association in months 18–24 and 24–30, and 
a decay to no association at months 30–36 (further details in the 
supplementary material, available online only).
Table 3 illustrates the implications of the WCD model for 
assessing relative risks associated with different patterns of 
past glucocorticoid exposure. The left-most column describes 
selected, clinically plausible patterns of current and past gluco-
corticoid doses. The second column describes the comparator 
(‘reference’) pattern, either a ‘non-user’, ie, a subject who did not 
use glucocorticoids throughout the past 3 years or a subject who 
had a similar dose and duration of glucocorticoid treatment in 
the more distant past. The right column shows the correspond-
ing adjusted OR, estimated through the ﬁ  nal WCD model that 
compares the risks between the two patterns in the same row. 
For example, a subject who was taking a daily dose of 5 mg PEQ 
for the past 6 months is estimated to have a 46% higher risk 
(OR 1.46) than a non-user (4th row, table 3). Different catego-
ries in table 3 are not mutually exclusive. For example, the OR 
for 5 mg PEQ taken for the past 6 months is a combination of 
the risk associated with 5 mg PEQ taken for the past 3 months 
(reported in the line above, OR 1.30) plus the risk from 5 mg 
PEQ taken 3–6 months ago. Overall, table 3 demonstrates that 
the risks vary substantially with dosage, duration and timing of 
the glucocorticoid treatment, and that the timing of discontinu-
ation has a notable impact on infection risk.
DISCUSSION
This study conﬁ  rms that glucocorticoid therapy is associated 
with serious infection in older patients with RA. We have rep-
licated previous reports of an increased risk using conventional 
models of exposure. For example, we have shown in model 
1 an OR for current exposure of 1.84 (95% CI 1.64 to 2.06), 
which compares with previous estimates using the same anal-
ysis model of between 1.9 and 2.1.13–15 Similarly, our OR for 
recent exposure (2.26, 95% CI 2.02 to 2.54, model 3) is similar 
to a previous estimate of 2.56 (95% CI 2.29 to 2.85),16 and for 
ever exposed our estimate of 1.72 (95% CI 1.53 to 1.94) from 
model 4 overlaps with a published estimate of 2.2 (95% CI 1.5 
to 3.4).12 Furthermore, our dose-speciﬁ  c estimates are also simi-
lar to those published analyses that accounted for glucocorticoid 
doses. In our study, 5 mg PEQ was associated with an OR of 
1.4–1.6 (models 6 and 7 in table 2), compared with previous esti-
mates of 1.3–1.5 for 1–5 mg PEQ and 1.5–2.1 for 5–10 mg PEQ.14 
15 26 27 More importantly, however, our knowledge of the rela-
tionship between dynamic glucocorticoid therapy and infection 
risk has been extended by applying novel methodology. Indeed, 
our results clearly demonstrate the importance of the cumula-
tive effects of the past use of glucocorticoids on serious infec-
tion risk, and accounting for differential impact of glucocorticoid 
doses taken at different times in the past.
Conventional drug exposure models rely on rather improba-
ble assumptions about the relative importance of previous ther-
apy. ‘Current exposure’ assumes any previous treatment has no 
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different recovery interval following discontinuation of therapy, 
as discussed above. A further and indirect mechanism may be 
the effect of glucocorticoids on the severity of, or host response 
to, infection, perhaps reﬂ  ecting the consequences of prolonged 
adrenal suppression. Finally, glucocorticoid therapy may act as 
a marker for ongoing disease activity and/or disability. Patients 
who used glucocorticoid therapy 2 years ago may be more likely 
to have high current disability, which is a known risk factor for 
serious infection.29 We were unable to test the reasons for the 
pattern of association within this study, but future research may 
explore the above conjectures.
This observational study has some limitations. We did not 
have measures of adherence, and so our estimates derived 
from dispensing data may underestimate the true risk, even if 
they are unlikely to affect the comparisons between alternative 
models. Confounding is an important consideration. We have 
adjusted for concomitant DMARD therapies and co-morbidities 
that might be associated with both glucocorticoid exposure 
and infection. No direct measures of RA disease activity exist 
within the administrative database so, similar to other studies, 
we adjusted for surrogate measures including the number of 
rheumatologist visits and concomitant NSAID use.16 30 While 
residual confounding by disease activity will remain, we have 
previously shown that it cannot fully explain the observed rela-
tionship between glucocorticoid therapy and infection risk.30 
Importantly, it is unlikely to confound the comparisons of risks 
associated with different patterns of past glucocorticoid use and 
of goodness of ﬁ  t of the different exposure models.18 31
Comprehensive prescription data were available only for 
patients aged 65 years or older. While restriction to this age group 
may limit generalisability, we would not anticipate the shape of 
the relationship between glucocorticoid therapy and infection 
risk differing signiﬁ  cantly in other age groups of patients with 
RA. Furthermore, replication of previous ﬁ  ndings using conven-
tional models is reassuring.
CONCLUSION
We have shown that a WCD model applied to glucocorticoid 
use in older patients with RA provides a far superior ﬁ  t than 
all conventional models. The results conﬁ  rm that glucocorticoid 
therapy is associated with an increased risk of infection when 
the risk is dependent on the recency of treatment. Contrary to 
the assumptions of many conventional models, doses 2 years 
ago still have an inﬂ  uence on infection risk.
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